Front Row Advisors LLC Hutchmed (China) LTD Transaction History

Front Row Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$8.59 - $20.77 $386 - $934	-45 Reduced 47.37%	50 $1,000
Q1 2022 May 11, 2022	BUY	$15.52 - $35.65 $77 - $178	5 Added 5.56%	95 $1,000
Q3 2021 Nov 03, 2021	SELL	$35.66 - $42.94 $106 - $128	-3 Reduced 3.23%	90 $3,000
Q2 2021 Aug 23, 2021	BUY	$23.7 - $39.27 $118 - $196	5 Added 5.68%	93 $4,000
Q1 2021 Apr 28, 2021	BUY	$27.01 - $36.8 $54 - $73	2 Added 2.33%	88 $2,000
Q3 2020 Nov 30, 2020	BUY	$25.8 - $34.61 $2,218 - $2,976	86 New	86 $3,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.9B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Front Row Advisors LLC with notifications on news.